BR0312896A - Glicanos e glicopeptìdeos de campylobacter - Google Patents

Glicanos e glicopeptìdeos de campylobacter

Info

Publication number
BR0312896A
BR0312896A BR0312896-2A BR0312896A BR0312896A BR 0312896 A BR0312896 A BR 0312896A BR 0312896 A BR0312896 A BR 0312896A BR 0312896 A BR0312896 A BR 0312896A
Authority
BR
Brazil
Prior art keywords
galnac
glycan
campylobacter
bac
antibodies
Prior art date
Application number
BR0312896-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Noel M Young
Jean Robert Brisson
John Francis Kelly
David C Watson
Christine M Szymanski
Harold C Jarrell
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Publication of BR0312896A publication Critical patent/BR0312896A/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/56922Campylobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/105Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
BR0312896-2A 2002-08-01 2003-07-30 Glicanos e glicopeptìdeos de campylobacter BR0312896A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39973502P 2002-08-01 2002-08-01
PCT/CA2003/001156 WO2004013151A2 (en) 2002-08-01 2003-07-30 Campylobacter glycans and glycopeptides

Publications (1)

Publication Number Publication Date
BR0312896A true BR0312896A (pt) 2005-06-14

Family

ID=31495764

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312896-2A BR0312896A (pt) 2002-08-01 2003-07-30 Glicanos e glicopeptìdeos de campylobacter

Country Status (9)

Country Link
US (1) US7598354B2 (https=)
EP (1) EP1527080B1 (https=)
JP (1) JP4718174B2 (https=)
CN (1) CN1671722A (https=)
AU (1) AU2003254665C1 (https=)
BR (1) BR0312896A (https=)
CA (1) CA2494223C (https=)
ES (1) ES2391525T3 (https=)
WO (1) WO2004013151A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
IL163806A0 (en) 2002-03-07 2005-12-18 Eidgenoess Tech Hochschule System and method for the production of recombinant glycosylated proteins in a prokaryotic host
AU2002952121A0 (en) * 2002-10-17 2002-10-31 Alchemia Limited Novel carbohydrate based anti-bacterials
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
JP2007515410A (ja) * 2003-12-03 2007-06-14 ネオス テクノロジーズ インコーポレイテッド GlycoPEG化卵胞刺激ホルモン
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
ES2353814T3 (es) * 2005-05-11 2011-03-07 Eth Zuerich Proteinas n-glicosiladas recombinantes de celulas procariotas.
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
HRP20130382T1 (hr) 2007-04-03 2013-05-31 Biogenerix Ag Postupci lijeäśenja pomoä†u glikopegiliranog g-csf
CA2690611C (en) 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
CN107119095B (zh) 2008-01-03 2022-07-05 康乃尔研究基金会有限公司 原核生物中的糖基化蛋白表达
CA2711503A1 (en) * 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
CN101983070B (zh) 2008-02-20 2016-03-30 格林考瓦因有限公司 由来源于原核细胞的重组n-糖基化蛋白制备生物共轭物
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
PL2411503T3 (pl) * 2009-03-27 2018-01-31 Eidgenoessische Technische Hochschule Zuerich Salmonella enterica prezentująca n-glikan z c. jejuni lub jego pochodne
NO2501406T3 (https=) 2009-11-19 2018-05-19
PT2545081E (pt) * 2010-02-11 2015-05-18 Univ Alberta Compostos de glicano ligados por n
US8841099B2 (en) * 2010-04-20 2014-09-23 National Research Council Of Canada Cell-based production of nonulosonates
EP3281639B1 (en) 2010-05-06 2020-11-11 GlaxoSmithKline Biologicals S.A. Capsular gram-positive bacteria bioconjugate vaccines
US9308246B2 (en) 2010-05-28 2016-04-12 The United States Of America As Represented By The Secretary Of The Navy Capsule composition for use as immunogen against Campylobacter jejuni
JP6135046B2 (ja) * 2012-04-20 2017-05-31 株式会社島津製作所 糖ペプチドの質量分析法
RU2671473C2 (ru) 2013-04-05 2018-10-31 Де Гавенерс Оф Де Юниверсити Оф Альберта Вакцина против кампилобактериоза
HK1246600B (en) * 2015-01-26 2020-04-09 Cadena Bio, Inc. Oligosaccharide compositions for use animal feed and methods of producing thereof
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
WO2019035916A1 (en) 2017-08-15 2019-02-21 Northwestern University DESIGN OF PROTEIN GLYCOSYLATION SITES BY RAPID EXPRESSION AND CHARACTERIZATION OF N-GLYCOSYLTRANSFERASES
EP3727437A4 (en) * 2017-12-19 2021-09-08 The Governors of the University of Alberta SURFACE GLYCANES OF CLOSTRIDIUM PERFRINGENS AND ASSOCIATED USES
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
WO2019204346A1 (en) 2018-04-16 2019-10-24 Northwestern University METHODS FOR CO-ACTIVATING IN VITRO NON-STANDARD AMINO ACID (nsAA) INCORPORATION AND GLYCOSYLATION IN CRUDE CELLLYSATES
US12098433B2 (en) 2018-08-03 2024-09-24 Northwestern University On demand, portable, cell-free molecular sensing platform
CN113646438A (zh) 2019-01-11 2021-11-12 西北大学 在原核生物细胞裂解物中合成生物缀合物疫苗
US12325884B2 (en) 2019-03-04 2025-06-10 Northwestern University Riboswitch-based fluoride sensing in cell-free extract
US12226410B2 (en) 2019-10-18 2025-02-18 Northwestern University Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6
CN115135771A (zh) 2019-10-25 2022-09-30 西北大学 用于富集膜泡和增加糖蛋白产量的无细胞提取物制备方案
WO2022256920A1 (en) * 2021-06-07 2022-12-15 The University Of British Columbia Acholetin biopolymers and methods for enzymatic synthesis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5200344A (en) * 1990-11-13 1993-04-06 Blaser Martin J Diagnostic testing for campylobacter jejuni or campylobacter coli infections using novel antigens
JPH09502604A (ja) * 1993-08-27 1997-03-18 エンテリック リサーチ ラボラトリーズ インコーポレイテッド Campylobacterjejuni抗原、並びにそれらの製造及び利用
ATE195147T1 (de) * 1994-09-06 2000-08-15 Ab Bioflexin Aminosäuren konjugaten
US5840547A (en) * 1995-01-05 1998-11-24 Ramot University Authority For Applied Research & Indfustrial Development Ltd. Bioemulsifiers
US6676946B2 (en) * 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
US6699705B2 (en) * 1999-02-01 2004-03-02 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
AU3513500A (en) * 1999-03-05 2000-09-21 Trustees Of Tufts College Emulsan and emulsan analogs immunization formulations and use
US6512014B2 (en) * 2000-12-13 2003-01-28 Ramot University Authority For Applied Research And Industrial Development Limited Compositions containing bioemulsifiers and a method for their preparation
ES2411007T3 (es) * 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US20030232401A1 (en) * 2002-06-12 2003-12-18 Pugia Michael J. Bacterial test method by glycated label binding
AU2006295017B2 (en) * 2005-09-21 2010-06-17 The United States Of America As Represented By The Secretary Of The Navy Immunogenic capsule composition for use as a vaccine component against Campylobacter jejuni

Also Published As

Publication number Publication date
CA2494223C (en) 2012-10-02
AU2003254665C1 (en) 2010-08-19
US7598354B2 (en) 2009-10-06
EP1527080B1 (en) 2012-06-20
EP1527080A2 (en) 2005-05-04
WO2004013151A3 (en) 2004-07-01
ES2391525T3 (es) 2012-11-27
CA2494223A1 (en) 2004-02-12
AU2003254665B2 (en) 2010-01-28
CN1671722A (zh) 2005-09-21
JP2005534752A (ja) 2005-11-17
US20060165728A1 (en) 2006-07-27
WO2004013151A2 (en) 2004-02-12
JP4718174B2 (ja) 2011-07-06
AU2003254665A1 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
BR0312896A (pt) Glicanos e glicopeptìdeos de campylobacter
León-Sicairos et al. Amoebicidal activity of milk, apo-lactoferrin, sIgA and lysozyme
Hoyle The influenza viruses
Paba et al. Proteomic analysis of the human pathogen Trypanosoma cruzi
Goldsmit et al. An improved method for the isolation and identification of bluetongue virus by intravenous inoculation of embryonating chicken eggs
Zhai et al. Enhanced immune responses of chickens to oral vaccination against infectious bursal disease by ginseng stem-leaf saponins
BR9912178A (pt) Vacinas de peptìdeo sintéticas para febre aftosa
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
Bittar et al. Effects of injectable trace minerals on the immune response to Mannheimia haemolytica and Pasteurella multocida following vaccination of dairy calves with a commercial attenuated-live bacterin vaccine
ECSP024257A (es) Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas
WO2021233885A1 (en) Mimotope peptides of the spike protein from the sars-cov-2 virus
Hajnicka et al. Tick salivary gland extracts promote virus growth in vitro
US20200069781A1 (en) Immunogenic lhrh composition and use thereof in pigs
Acosta et al. Structural and immunological characterization of sulphatides: relevance of sulphate moieties in Trypanosoma cruzi glycoconjugates
LEACH et al. A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants
Neurath et al. Solubilization and some properties of the erythrocyte receptor for adenovirus type 7 haemagglutinin
US20240218020A1 (en) Peptides inhibiting covid-19
Ansari et al. An experimental and clinical evaluation of immuno-modulating potential of human placental extract
CN1341150A (zh) 疟疾疫苗
US4083959A (en) Therapeutical method for treating infection of mink hemorrhagic pneumonitis
Qureshi et al. A novel phage based marker vaccine and DI VA assay for hemorrhagic septicemia in bovines
BR0001559A (pt) Vacina para a prevenção da colonização de campylobacter em animais, proteìna antigênica de campylobacter, uso de uma proteìna antigênica, vacina para a prevenção da colonização de campylobacter jejuni em galináceos, uso de anticorpos contra uma cepa de campylobacter sem flagelos, ou contra a proteìna antigênica, e, processo para a preparação de uma vacina
Peter et al. Detection of bovine viral diarrhea virus antibodies in camels (Camelus dromedarius) in Maiduguri, Nigeria
BRPI0503187B1 (pt) Composição compreendendo fucose manose ligand (fml) e saponina, para uso como uma vacina bloqueadora contra a transmissão de leishmaniose visceral canina
Trybala et al. An Intradermal Test for the Diagnosis of BHV‐1 Infection. The Effect of Repeated Testing on the Immune Status of Cattle

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2162 DE 12/06/2012.